inked a collaboration and license agreement with University College London
(UCL) related to developing stem cell-based therapies for certain ophthalmic conditions. The partnership will examine how human embryonic stem cells differentiate into retinal pigment epithelium (RPE) with the goal of developing treatments primarily for wet and dry age-related macular degeneration.
While Pfizer’s contributions will be in the form of design and execution of clinical studies, interaction with global regulators, as well as product manufacturing, UCL will focus on research and preclinical studies.
Pfizer will provide research funding to UCL. The firm will have exclusive, worldwide rights to develop and commercialize an RPE stem cell-based therapeutic in the ophthalmology field. After the completion of preclinical safety studies, Pfizer will have the option to conduct clinical development and commercialization.
Recent Pfizer News
GSK and Pfizer Create HIV-Focused Company (Apr. 16, 2009)
Pfizer to Increase Stake in Pfizer India with $136.5M Offer (Apr. 13, 2009)
Pfizer Logs Another Misstep in Late-Stage Development (Apr. 2, 2009)
MannKind to Buy Pfizer’s Frankfurt Insulin Production Plant for $33M (Mar. 9, 2009)
Pfizer Gains 39 Generic Therapies from Aurobindo (Mar. 3, 2009)
Other News in Stem Cell Therapeutics
Neuralstem's ALS Trial with Stem Cell Therapy Delayed (Feb. 20, 2009)
VistaGen and Capsant to Develop Stem Cell Technology for Drug R&D (Jan. 15, 2009)
Pluripotent Stem Cells Created for 10 Diseases (Aug. 7, 2008)
Gamida Obtains Rights to Amgen Cytokines to Produce Stem Cell Cancer Drug (July 21, 2008)
Osiris Obtains $2M from JDRF with Clinical Advancement of Stem Cell Therapy (June 25, 2008)